Concepts (214)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Heart Failure | 20 | 2024 | 11781 | 1.520 |
Why?
|
Stroke Volume | 17 | 2024 | 5470 | 1.150 |
Why?
|
Exercise Tolerance | 8 | 2023 | 809 | 1.130 |
Why?
|
Sex Characteristics | 5 | 2023 | 2632 | 1.080 |
Why?
|
Infertility | 2 | 2023 | 656 | 1.060 |
Why?
|
Sex Factors | 11 | 2024 | 10493 | 1.040 |
Why?
|
Purinergic P2Y Receptor Antagonists | 2 | 2017 | 377 | 0.920 |
Why?
|
Ventricular Function, Left | 10 | 2024 | 3840 | 0.840 |
Why?
|
Menopause, Premature | 1 | 2023 | 126 | 0.810 |
Why?
|
Cardiovascular Diseases | 8 | 2024 | 15651 | 0.770 |
Why?
|
Pulmonary Edema | 2 | 2021 | 406 | 0.740 |
Why?
|
Early Termination of Clinical Trials | 1 | 2021 | 70 | 0.740 |
Why?
|
Exercise Test | 9 | 2024 | 2120 | 0.690 |
Why?
|
Pheochromocytoma | 1 | 2021 | 328 | 0.650 |
Why?
|
Drug Therapy | 1 | 2021 | 502 | 0.590 |
Why?
|
Menopause | 2 | 2023 | 1639 | 0.580 |
Why?
|
Pregnancy Complications, Hematologic | 1 | 2018 | 177 | 0.550 |
Why?
|
Inflammation Mediators | 2 | 2022 | 1874 | 0.530 |
Why?
|
Mitral Valve Stenosis | 1 | 2018 | 346 | 0.530 |
Why?
|
Adrenal Gland Neoplasms | 1 | 2021 | 734 | 0.510 |
Why?
|
Blood Coagulation Disorders | 1 | 2018 | 349 | 0.490 |
Why?
|
Blood Proteins | 1 | 2019 | 1153 | 0.470 |
Why?
|
Women | 1 | 2016 | 226 | 0.470 |
Why?
|
Pregnancy Complications, Cardiovascular | 1 | 2018 | 512 | 0.450 |
Why?
|
Oxygen Consumption | 1 | 2020 | 1840 | 0.440 |
Why?
|
Muscle Fatigue | 1 | 2013 | 92 | 0.430 |
Why?
|
Respiratory Muscles | 1 | 2013 | 142 | 0.430 |
Why?
|
Adrenergic beta-2 Receptor Agonists | 1 | 2013 | 108 | 0.420 |
Why?
|
Albuterol | 1 | 2013 | 211 | 0.420 |
Why?
|
Pulmonary Wedge Pressure | 3 | 2024 | 273 | 0.410 |
Why?
|
Blood Coagulation | 1 | 2018 | 1154 | 0.410 |
Why?
|
Acidosis, Lactic | 1 | 2013 | 145 | 0.400 |
Why?
|
Physicians, Women | 1 | 2018 | 488 | 0.400 |
Why?
|
Obesity | 8 | 2024 | 12843 | 0.380 |
Why?
|
Cardiology | 2 | 2023 | 1712 | 0.370 |
Why?
|
Aspirin | 1 | 2022 | 3347 | 0.360 |
Why?
|
Dyspnea | 3 | 2024 | 1346 | 0.360 |
Why?
|
Hypertension | 5 | 2023 | 8526 | 0.360 |
Why?
|
Proteomics | 2 | 2022 | 3760 | 0.320 |
Why?
|
Atrial Fibrillation | 3 | 2023 | 5162 | 0.310 |
Why?
|
Myocardium | 1 | 2021 | 4673 | 0.310 |
Why?
|
Physician-Patient Relations | 1 | 2021 | 3215 | 0.290 |
Why?
|
Female | 39 | 2024 | 387920 | 0.280 |
Why?
|
Phenotype | 2 | 2021 | 16478 | 0.270 |
Why?
|
Cardiomyopathies | 1 | 2018 | 1932 | 0.270 |
Why?
|
Risk Factors | 14 | 2023 | 73860 | 0.270 |
Why?
|
Humans | 53 | 2024 | 755533 | 0.270 |
Why?
|
Inflammation | 4 | 2023 | 10717 | 0.260 |
Why?
|
Aortic Valve Stenosis | 1 | 2018 | 2066 | 0.260 |
Why?
|
Insulin Resistance | 5 | 2023 | 3944 | 0.250 |
Why?
|
Eicosanoids | 2 | 2023 | 278 | 0.250 |
Why?
|
Middle Aged | 24 | 2024 | 218055 | 0.240 |
Why?
|
Pre-Eclampsia | 2 | 2024 | 1219 | 0.240 |
Why?
|
Adrenomedullin | 1 | 2023 | 84 | 0.220 |
Why?
|
Coronary Artery Disease | 3 | 2018 | 6616 | 0.220 |
Why?
|
Cardiac Surgical Procedures | 1 | 2018 | 3632 | 0.210 |
Why?
|
Hemodynamics | 4 | 2021 | 4186 | 0.210 |
Why?
|
Anticoagulants | 1 | 2018 | 4862 | 0.210 |
Why?
|
Purpura, Thrombotic Thrombocytopenic | 1 | 2024 | 130 | 0.210 |
Why?
|
Male | 28 | 2024 | 356577 | 0.200 |
Why?
|
Ventricular Remodeling | 3 | 2023 | 1247 | 0.190 |
Why?
|
Hematemesis | 1 | 2021 | 22 | 0.190 |
Why?
|
Hierarchy, Social | 1 | 2021 | 23 | 0.190 |
Why?
|
Leptospirosis | 1 | 2021 | 28 | 0.190 |
Why?
|
Vascular Resistance | 1 | 2024 | 931 | 0.190 |
Why?
|
Hypertension, Pulmonary | 2 | 2023 | 1562 | 0.190 |
Why?
|
Vascular Endothelial Growth Factor Receptor-1 | 1 | 2024 | 557 | 0.180 |
Why?
|
Adiponectin | 3 | 2023 | 1113 | 0.180 |
Why?
|
C-Reactive Protein | 3 | 2021 | 3812 | 0.180 |
Why?
|
Risk Reduction Behavior | 2 | 2017 | 1097 | 0.180 |
Why?
|
Blood Sedimentation | 1 | 2020 | 234 | 0.170 |
Why?
|
Hemoptysis | 1 | 2021 | 152 | 0.170 |
Why?
|
Electrocardiography | 4 | 2023 | 6387 | 0.170 |
Why?
|
Verbal Behavior | 1 | 2021 | 334 | 0.170 |
Why?
|
Myocardial Infarction | 2 | 2023 | 11871 | 0.170 |
Why?
|
Fibrin Fibrinogen Degradation Products | 1 | 2020 | 419 | 0.160 |
Why?
|
Atrial Function, Right | 1 | 2018 | 32 | 0.160 |
Why?
|
Leptin | 3 | 2023 | 1595 | 0.160 |
Why?
|
Abortion, Induced | 1 | 2024 | 456 | 0.150 |
Why?
|
Pulmonary Gas Exchange | 1 | 2020 | 378 | 0.150 |
Why?
|
Hypertension, Pregnancy-Induced | 1 | 2024 | 524 | 0.150 |
Why?
|
Coronary Circulation | 1 | 2024 | 1580 | 0.150 |
Why?
|
Adipokines | 1 | 2020 | 311 | 0.150 |
Why?
|
Cardiac Volume | 1 | 2018 | 199 | 0.150 |
Why?
|
Lung | 3 | 2021 | 9918 | 0.140 |
Why?
|
Adult | 20 | 2024 | 217986 | 0.140 |
Why?
|
Aged | 14 | 2024 | 167376 | 0.140 |
Why?
|
Metabolic Networks and Pathways | 1 | 2021 | 787 | 0.140 |
Why?
|
Interleukin-6 | 3 | 2023 | 3203 | 0.140 |
Why?
|
Fatal Outcome | 1 | 2021 | 1831 | 0.140 |
Why?
|
Respiratory Function Tests | 1 | 2021 | 1674 | 0.130 |
Why?
|
Cardiovascular System | 1 | 2024 | 848 | 0.130 |
Why?
|
Cardiac Resynchronization Therapy | 1 | 2022 | 554 | 0.130 |
Why?
|
Logistic Models | 2 | 2021 | 13315 | 0.130 |
Why?
|
Shock, Cardiogenic | 1 | 2021 | 718 | 0.130 |
Why?
|
Pregnancy | 6 | 2024 | 29543 | 0.130 |
Why?
|
Asymptomatic Diseases | 1 | 2018 | 570 | 0.120 |
Why?
|
Primary Prevention | 1 | 2022 | 1194 | 0.120 |
Why?
|
Heart Valve Diseases | 1 | 2023 | 1049 | 0.120 |
Why?
|
Severity of Illness Index | 3 | 2024 | 15746 | 0.120 |
Why?
|
Radiography, Thoracic | 1 | 2021 | 1289 | 0.120 |
Why?
|
Internal Medicine | 1 | 2021 | 1033 | 0.110 |
Why?
|
Patient Preference | 1 | 2021 | 908 | 0.110 |
Why?
|
Health Services Research | 1 | 2021 | 1810 | 0.110 |
Why?
|
Mitral Valve Insufficiency | 1 | 2023 | 1418 | 0.110 |
Why?
|
Ventricular Dysfunction, Left | 1 | 2024 | 2129 | 0.110 |
Why?
|
Diabetes Mellitus | 2 | 2023 | 5843 | 0.110 |
Why?
|
Echocardiography | 3 | 2024 | 4957 | 0.100 |
Why?
|
Women's Health | 1 | 2022 | 2053 | 0.100 |
Why?
|
Linear Models | 2 | 2020 | 5863 | 0.100 |
Why?
|
Heart Atria | 1 | 2018 | 1344 | 0.100 |
Why?
|
Adiposity | 1 | 2021 | 1846 | 0.100 |
Why?
|
Massachusetts | 2 | 2021 | 8735 | 0.090 |
Why?
|
Cardiovascular Agents | 1 | 2017 | 866 | 0.090 |
Why?
|
Arthroplasty, Replacement, Knee | 1 | 2021 | 1346 | 0.090 |
Why?
|
Coronary Vessels | 2 | 2024 | 3116 | 0.090 |
Why?
|
Risk | 1 | 2022 | 9624 | 0.090 |
Why?
|
Longitudinal Studies | 2 | 2023 | 14383 | 0.090 |
Why?
|
Administration, Inhalation | 1 | 2013 | 1150 | 0.090 |
Why?
|
Adipose Tissue | 1 | 2022 | 3290 | 0.090 |
Why?
|
Outpatients | 1 | 2018 | 1593 | 0.090 |
Why?
|
Blood Pressure | 2 | 2022 | 8494 | 0.080 |
Why?
|
Quality of Life | 2 | 2022 | 13201 | 0.080 |
Why?
|
Prognosis | 4 | 2023 | 29423 | 0.080 |
Why?
|
Education, Medical | 1 | 2021 | 1719 | 0.080 |
Why?
|
Anti-Retroviral Agents | 1 | 2018 | 1773 | 0.080 |
Why?
|
Treatment Outcome | 6 | 2024 | 64535 | 0.080 |
Why?
|
Pregnancy Outcome | 1 | 2018 | 2869 | 0.070 |
Why?
|
MicroRNAs | 1 | 2023 | 3779 | 0.070 |
Why?
|
Curriculum | 1 | 2021 | 3670 | 0.070 |
Why?
|
Atherosclerosis | 1 | 2023 | 3510 | 0.070 |
Why?
|
Prospective Studies | 6 | 2022 | 53991 | 0.070 |
Why?
|
Plaque, Atherosclerotic | 1 | 2017 | 1504 | 0.070 |
Why?
|
Coronary Angiography | 1 | 2017 | 4554 | 0.060 |
Why?
|
Registries | 1 | 2021 | 8405 | 0.060 |
Why?
|
Mortality | 1 | 2016 | 2899 | 0.060 |
Why?
|
Platelet Aggregation Inhibitors | 1 | 2017 | 3177 | 0.060 |
Why?
|
Hospitalization | 2 | 2021 | 10683 | 0.060 |
Why?
|
HSP27 Heat-Shock Proteins | 1 | 2024 | 67 | 0.060 |
Why?
|
Plasma Exchange | 1 | 2024 | 157 | 0.050 |
Why?
|
Epoxy Compounds | 1 | 2023 | 135 | 0.050 |
Why?
|
Resistin | 1 | 2023 | 172 | 0.050 |
Why?
|
Linoleic Acid | 1 | 2023 | 159 | 0.050 |
Why?
|
Colorectal Neoplasms | 1 | 2022 | 6819 | 0.050 |
Why?
|
Antigen-Antibody Complex | 1 | 2024 | 512 | 0.050 |
Why?
|
Internship and Residency | 1 | 2021 | 5831 | 0.040 |
Why?
|
Plasmapheresis | 1 | 2021 | 206 | 0.040 |
Why?
|
Bundle-Branch Block | 1 | 2022 | 281 | 0.040 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2017 | 10246 | 0.040 |
Why?
|
Fractional Flow Reserve, Myocardial | 1 | 2024 | 331 | 0.040 |
Why?
|
Microvessels | 1 | 2024 | 571 | 0.040 |
Why?
|
Live Birth | 1 | 2023 | 507 | 0.040 |
Why?
|
Microcirculation | 1 | 2024 | 1280 | 0.040 |
Why?
|
Predictive Value of Tests | 3 | 2021 | 15197 | 0.040 |
Why?
|
Postoperative Complications | 1 | 2021 | 15576 | 0.040 |
Why?
|
Pulmonary Disease, Chronic Obstructive | 1 | 2013 | 3155 | 0.040 |
Why?
|
Videoconferencing | 1 | 2021 | 197 | 0.040 |
Why?
|
Mexico | 1 | 2021 | 747 | 0.040 |
Why?
|
American Heart Association | 1 | 2023 | 1081 | 0.040 |
Why?
|
Diagnosis, Differential | 1 | 2013 | 12926 | 0.040 |
Why?
|
Signal Transduction | 1 | 2021 | 23278 | 0.040 |
Why?
|
Retrospective Studies | 2 | 2023 | 79686 | 0.040 |
Why?
|
Communication Barriers | 1 | 2021 | 412 | 0.040 |
Why?
|
Postpartum Period | 1 | 2024 | 1166 | 0.040 |
Why?
|
Delayed Diagnosis | 1 | 2021 | 458 | 0.040 |
Why?
|
Risk Assessment | 1 | 2018 | 23956 | 0.030 |
Why?
|
Odds Ratio | 2 | 2020 | 9720 | 0.030 |
Why?
|
Transforming Growth Factor beta | 1 | 2023 | 1945 | 0.030 |
Why?
|
Congresses as Topic | 1 | 2021 | 797 | 0.030 |
Why?
|
Natriuretic Peptide, Brain | 1 | 2024 | 1696 | 0.030 |
Why?
|
Autoantibodies | 1 | 2024 | 2092 | 0.030 |
Why?
|
Bronchoscopy | 1 | 2021 | 898 | 0.030 |
Why?
|
Travel | 1 | 2021 | 784 | 0.030 |
Why?
|
Antibodies, Bacterial | 1 | 2021 | 1460 | 0.030 |
Why?
|
Prevalence | 2 | 2024 | 15589 | 0.030 |
Why?
|
Mitral Valve | 1 | 2023 | 1483 | 0.030 |
Why?
|
Emigrants and Immigrants | 1 | 2021 | 535 | 0.030 |
Why?
|
Recombinant Proteins | 1 | 2024 | 6529 | 0.030 |
Why?
|
Genome-Wide Association Study | 2 | 2024 | 12491 | 0.030 |
Why?
|
Gastrointestinal Hemorrhage | 1 | 2021 | 1132 | 0.030 |
Why?
|
Fever | 1 | 2021 | 1613 | 0.030 |
Why?
|
Follow-Up Studies | 3 | 2020 | 39179 | 0.030 |
Why?
|
Arrhythmias, Cardiac | 1 | 2022 | 2247 | 0.030 |
Why?
|
Incidence | 2 | 2022 | 21239 | 0.030 |
Why?
|
Respiratory Insufficiency | 1 | 2020 | 1213 | 0.030 |
Why?
|
HIV Infections | 1 | 2018 | 17053 | 0.020 |
Why?
|
Body Mass Index | 2 | 2020 | 12838 | 0.020 |
Why?
|
Cholesterol, HDL | 1 | 2018 | 1812 | 0.020 |
Why?
|
Peptide Fragments | 1 | 2024 | 5087 | 0.020 |
Why?
|
Chi-Square Distribution | 1 | 2017 | 3469 | 0.020 |
Why?
|
Endothelial Cells | 1 | 2023 | 3514 | 0.020 |
Why?
|
Triglycerides | 1 | 2018 | 2470 | 0.020 |
Why?
|
Cholesterol | 1 | 2018 | 2919 | 0.020 |
Why?
|
Artificial Intelligence | 1 | 2023 | 2478 | 0.020 |
Why?
|
Education, Medical, Graduate | 1 | 2021 | 2332 | 0.020 |
Why?
|
Kidney | 1 | 2023 | 7009 | 0.020 |
Why?
|
Positron-Emission Tomography | 1 | 2024 | 6445 | 0.020 |
Why?
|
Patient Compliance | 1 | 2017 | 2684 | 0.020 |
Why?
|
Hospital Mortality | 1 | 2020 | 5400 | 0.020 |
Why?
|
Disease Progression | 1 | 2023 | 13427 | 0.020 |
Why?
|
Exercise | 1 | 2022 | 5763 | 0.020 |
Why?
|
Aged, 80 and over | 2 | 2020 | 58549 | 0.010 |
Why?
|
Blood Glucose | 1 | 2018 | 6347 | 0.010 |
Why?
|
Proportional Hazards Models | 1 | 2018 | 12500 | 0.010 |
Why?
|
Attitude of Health Personnel | 1 | 2017 | 3832 | 0.010 |
Why?
|
Health Knowledge, Attitudes, Practice | 1 | 2017 | 3948 | 0.010 |
Why?
|
Anti-Bacterial Agents | 1 | 2021 | 7342 | 0.010 |
Why?
|
Young Adult | 2 | 2018 | 58025 | 0.010 |
Why?
|
Genetic Predisposition to Disease | 1 | 2023 | 17703 | 0.010 |
Why?
|
Cohort Studies | 1 | 2021 | 41119 | 0.010 |
Why?
|
Tomography, X-Ray Computed | 1 | 2021 | 20404 | 0.010 |
Why?
|
Time Factors | 1 | 2017 | 39961 | 0.010 |
Why?
|
United States | 1 | 2023 | 71888 | 0.010 |
Why?
|
Adolescent | 1 | 2018 | 87236 | 0.010 |
Why?
|
Concepts
(214)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(107)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_